Compare · AZN vs LXRX
AZN vs LXRX
Side-by-side comparison of AstraZeneca PLC (AZN) and Lexicon Pharmaceuticals Inc. (LXRX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AZN and LXRX operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- AZN is the larger of the two at $563.07B, about 674.3x LXRX ($835.1M).
- Over the past year, AZN is down 3.1% and LXRX is up 152.3% - LXRX leads by 155.4 points.
- AZN has been more active in the news (21 items in the past 4 weeks vs 9 for LXRX).
- AZN has more recent analyst coverage (25 ratings vs 5 for LXRX).
- Company
- AstraZeneca PLC
- Lexicon Pharmaceuticals Inc.
- Price
- $182.51+0.46%
- $1.86-1.59%
- Market cap
- $563.07B
- $835.1M
- 1M return
- -0.13%
- -7.00%
- 1Y return
- -3.07%
- +152.31%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2026
- News (4w)
- 21
- 9
- Recent ratings
- 25
- 5
AstraZeneca PLC
AstraZeneca PLC discovers, develops, manufactures, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infection, neuroscience, and gastroenterology worldwide. The company's marketed products include Tagrisso, Lynparza, Imfinzi, Enhertu, Koselugo, Lumoxiti, Equidacent, Zoladex, Faslodex, Iressa, Arimidex, Casodex/Cosudex, and others for oncology diseases; Onglyza, Bydureon, Lokelma, Byetta, Qtern, Symlin, and others for cardiovascular, renal, and metabolism diseases; and Symbicort, Pulmicort, Fasenra, Daliresp/Daxas, Duaklir, Tudorza/Eklira, Bevespi, Breztri, Anifrolumab, and others for respiratory and immunology diseases. It also offers other medicines and COVID-19 products, including Synagis, Fluenz Tetra/FluMist Quadrivalent, Seroquel IR/Seroquel XR, Vimovo, Movantik/Moventig, Nexium, Losec/Prilosec, and COVID-19 Vaccine AstraZeneca. The company serves primary care and specialty care physicians through distributors and local representative offices. It has a collaboration agreement with Daiichi Sankyo to develop and commercialize DS-1062 for the treatment of trophoblast cell-surface antigen 2 (TROP2) tumor; AliveCor, Inc. to develop non-invasive potassium monitoring solutions; Massachusetts General Hospital to accelerate digital health solutions; Sanguina on smartphone application study for hemoglobin management in patients with anemia of chronic kidney disease; Alchemab to enhance prostate cancer research; and Proteros biostructures GmbH to discover and develop novel small molecules for the treatment of various types of cancer. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. It has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
Lexicon Pharmaceuticals Inc.
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; LX9211, which is in Phase II clinical development for the treatment of neuropathic pain; and LX2761. The company has strategic collaboration and license agreements with Bristol-Myers Squibb Company, and Genentech, Inc. Lexicon Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in The Woodlands, Texas.
Latest AZN
- NYSE Content Update: AstraZeneca Celebrates Largest Transfer in NYSE History
- Camizestrant Combination Delayed Time to First Progression by 55% and to Second Progression by 37% in Patients With Advanced HR-positive Breast Cancer With an Emergent ESR1 Tumor Mutation in SERENA-6 Trial
- SEC Form 6-K filed by AstraZeneca PLC
- SEC Form 6-K filed by AstraZeneca PLC
- IMFINZI® (durvalumab) plus IMJUDO® (tremelimumab-actl) combined with lenvatinib and TACE reduced the risk of disease progression or death by 30% in embolization-eligible unresectable liver cancer in EMERALD-3 Phase III trial
- SEC Form 6-K filed by AstraZeneca PLC
- IMFINZI® (durvalumab) approved in the US in first and only immunotherapy combination for patients with BCG-naïve, high-risk non-muscle-invasive bladder cancer
- SEC Form 25-NSE filed by AstraZeneca PLC
- SEC Form 6-K filed by AstraZeneca PLC
- SEC Form 6-K filed by AstraZeneca PLC
Latest LXRX
- Director Swain Judith L converted options into 89,312 shares, increasing direct ownership by 105% to 174,486 units (SEC Form 4)
- Director Sullivan Diane E. converted options into 89,312 shares, increasing direct ownership by 243% to 126,122 units (SEC Form 4)
- Director Sobecki Christopher J converted options into 89,312 shares, increasing direct ownership by 44% to 293,177 units (SEC Form 4)
- Director Cheung Ivan converted options into 89,312 shares (SEC Form 4)
- Director Amouyal Philippe converted options into 89,312 shares, increasing direct ownership by 31% to 374,486 units (SEC Form 4)
- Director Barker Sam L converted options into 89,312 shares, increasing direct ownership by 72% to 213,771 units (SEC Form 4)
- Director Debbane Raymond converted options into 89,312 shares, increasing direct ownership by 5% to 1,995,498 units (SEC Form 4)
- Lexicon to Present Data at the American Diabetes Association (ADA) 2026 Scientific Sessions
- Lexicon Pharmaceuticals to Present at the 2026 Jefferies Global Healthcare Conference
- Lexicon Pharmaceuticals to Present at the 4th Annual H.C. Wainwright BioConnect Investor Conference